Oral micoencapsulated live Saccharomyces cerevisiae cells for use in renal failure uremia: preparation and in vivo analysis.
Orally administrable alginate-poly-L-lysine-alginate (APA) microcapsules containing live yeast cells was investigated for use in renal failure. At all times, yeast cells remain inside the microcapsules, which are then excreted in the stool. During their gastrointestinal passage, small molecules, lik...
| Publicado en: | Journal of Biomedicine & Biotechnology pp. 7p - 8 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
2010
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105085287&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105085287 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11107243 137K jtl: Journal of Biomedicine & Biotechnology issn: 11107243 maglogo: N pubinfo: dt: 2010 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 105085287 105085287 2010758285 105085287 ppf: 7p ppct: 1 formats: fmt: @attributes: type: P tig: atl: Oral micoencapsulated live Saccharomyces cerevisiae cells for use in renal failure uremia: preparation and in vivo analysis. aug: au: Coussa R Martoni C Bhathena J Urbanska AM Prakash S affil: Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, Faculty of Medicine, McGill University, Duff Medical Building, 3775 University Street, Montréal, QC, Canada H3A 2B4 sug: subj: Cells Renal Insufficiency Therapy Uremia Yeasts Analysis of Variance Animal Studies Funding Source In Vivo Studies Rats ab: Orally administrable alginate-poly-L-lysine-alginate (APA) microcapsules containing live yeast cells was investigated for use in renal failure. At all times, yeast cells remain inside the microcapsules, which are then excreted in the stool. During their gastrointestinal passage, small molecules, like urea, diffuse into the yeast microcapsules where they are hydrolyzed. Orally administrating these microcapsules to uremic rats was found to decrease urea concentrations from 7.29±0.89 mmol/L to 6.12±0.90 mmol/L over a treatment period of eight weeks. After stopping the treatment, the urea concentrations increased back to uremic levels of 7.64±0.77 mmol/L. The analysis of creatinine concentrations averaged 39.19±4.33 micromol/L, 50.83±5.55 micromol/L, and 50.28±7.10 micromol/L for the normal-control, uremic-control and uremic-treatment groups, respectively. While creatinine concentrations for both uremic-control and uremic-treatment groups did not differ among each other (P>.05), they were, however, significantly higher than those of the normal control group (P<.05). Uric acid concentrations averaged 80.08±26.49 micromol/L, 99.92±26.55 micromol/L, and 86.49±28.42 micromol/L for the normal-control, uremic-control and uremic-treatment groups, respectively. There were no significant differences in both calcium and phosphate concentrations among all three groups (P>.05). The microbial populations of five tested types of bacteria were not substantially altered by the presence of the yeast APA encapsulated yeast (P>.05). pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|